Retatrutide
InterventionGLP-1 receptor agonists3 papers4 findings
- Human trial2
Outcomes
3Body weight
downin humans2
2 studies
Body weight
downin humans2
Retatrutide decreases body weight in humans (-17.6% (4-mg), -23.7% (9-mg), -25.0% (12-mg) vs -3.9% placebo).
Human trialsubcutaneous injection80 weeksn = 2,339
Retatrutide reduces weight and pain in adults with obesity · The New England journal of medicine · 29 Sep 2026
Retatrutide decreases body weight in humans (-13·8% (95% CI -15·8 to -11·8)).
Human trialin adults with obesity and type 2 diabetes12 mg80 weeks
Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial · Lancet (London, England) · 29 Sep 2026
Apnea-hypopnea index
downin humans1
1 study
Apnea-hypopnea index
downin humans1
Retatrutide decreases apnea-hypopnea index in humans.
Human trialobstructive sleep apneasubcutaneous injection80 weeksn = 243
Retatrutide reduces weight and pain in adults with obesity · The New England journal of medicine · 29 Sep 2026
WOMAC pain score
downin humans1
1 study
WOMAC pain score
downin humans1
Retatrutide decreases WOMAC pain score in humans.
Human trialknee osteoarthritissubcutaneous injection80 weeksn = 574
Retatrutide reduces weight and pain in adults with obesity · The New England journal of medicine · 29 Sep 2026
Latest
3Retatrutide reduces weight and pain in adults with obesity
Mean body weight fell up to 25.0% with retatrutide versus 3.9% on placebo over 80 weeks in adults with obesity.Mean body weight fell up to 25.0% with retatrutide versus 3.9% on placebo over 80 weeks in adults with obesity.